Company news

Gilead Sciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Kite Receives U.S. FDA Approval of New State-of-the-Art CAR T-Cell Therapy Manufacturing Facility in Maryland

April 18, 2022

Gilead Sciences to Release First Quarter 2022 Financial Results on Thursday, April 28, 2022

April 13, 2022

Gilead Sciences Announces $24 Million in Grants to Help End the HIV Epidemic for Everyone, Everywhere

March 27, 2022

Phase 3 TROPiCS-02 Study Met the Primary Endpoint of Progression-Free Survival in Late-Line HR+/HER2- Metastatic Breast Cancer

March 6, 2022

Gilead Receives Complete Response Letter From U.S. FDA for Investigational Lenacapavir Due to Vial Compatability Issues

February 28, 2022

New Clinical Data Support the Sustained Efficacy of Long-acting Lenacapavir, Gilead’s Investigational HIV-1 Capsid Inhibitor

February 15, 2022

Veklury® (Remdesivir) Retains Antiviral Activity Against Omicron, Delta and Other Emergent SARS-CoV-2 Variants in Multiple In Vitro Studies

February 10, 2022

Gilead Sciences Announces 2.8 Percent Increase in First Quarter 2022 Dividend

January 31, 2022

Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination With Azacitidine

January 24, 2022

FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression

January 20, 2022

Gilead Sciences to Release Fourth Quarter & Full Year 2021 Financial Results on Tuesday, February 1, 2022

January 17, 2022

Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy® in Combination With KEYTRUDA® in First-Line Metastatic Non-Small Cell Lung Cancer

January 9, 2022

Gilead Announces New England Journal of Medicine Publication of Data Demonstrating Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients With COVID-19

December 21, 2021

Gilead Announces Clinical Hold on Studies Evaluating Injectable Lenacapavir for HIV Treatment and Prevention Due to Vial Quality Concerns

December 20, 2021

Gilead and AWS Collaborate on Development and Delivery of New Medicines for Patients

November 28, 2021

Trodelvy® (sacituzumab govitecan) Granted European Commission Marketing Authorization for Treatment of Metastatic Triple-Negative Breast Cancer in Second Line

November 22, 2021

Gilead Submits Biologics License Application to U.S. Food and Drug Administration for Bulevirtide, an Investigational Treatment for People Living With Chronic Hepatitis Delta

November 18, 2021

Gilead Exercises Options to Three Arcus Biosciences Clinical-Stage Programs and Adds Research Collaboration

November 17, 2021

Clinical and Patient-Reported Outcomes in People Living With HIV on Biktarvy® in Observational BICSTaR Study Demonstrate Consistent Efficacy Profile in Real-World Setting

October 28, 2021

Gilead Announces Clinical Trial Collaboration With Merck to Evaluate Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) in Patients With First-Line Metastatic Triple-Negative Breast Cancer

October 27, 2021

Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults

October 25, 2021

Gilead Presents Long-Term Switch Data Reinforcing Biktarvy® as a Treatment Option for a Broad Range of People Living With HIV

October 20, 2021

Gilead Sciences Announces Veklury® Donations to Help Address the Ongoing COVID-19 Crisis in Indonesia and Armenia

October 18, 2021

U.S. Food and Drug Administration Approves Expanded Indication of Gilead’s Biktarvy® for Treatment of HIV-1 in Pediatric Populations

October 17, 2021

Gilead Sciences to Release Third Quarter 2021 Financial Results on Thursday, October 28, 2021

October 13, 2021

U.S. FDA Approves Kite’s Tecartus® as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

September 30, 2021

Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Earlier Use of Yescarta® in Large B-cell Lymphoma

September 29, 2021

Gilead Marks Fifth Approval for Trodelvy® in Metastatic Triple-Negative Breast Cancer Under Project Orbis Initiative with Health Canada Authorization

September 26, 2021

European Medicines Agency Validates Gilead’s Marketing Authorization Application for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options

August 18, 2021

Gilead Sciences Endows Its Foundation With More Than $200 Million to Support Health Justice, Community Giving and Employee Match Program

August 10, 2021

Kite and Appia Bio Announce Collaboration to Research and Develop Allogeneic Cell Therapies for Cancer

August 4, 2021

Gilead Sciences Announces Second Quarter 2021 Financial Results

July 28, 2021

Gilead Sciences to Release Second Quarter 2021 Financial Results on Thursday, July 29, 2021

July 14, 2021

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options

June 27, 2021

Kite Joint Venture - Fosun Kite - Gains the First CAR T-cell Therapy Approval in China

June 22, 2021

Gilead’s Veklury® (Remdesivir) Associated With a Reduction in Mortality Rate in Hospitalized Patients With COVID-19 Across Three Analyses of Large Retrospective Real-World Data Sets

June 20, 2021

Kite's Tecartus® Demonstrates High Response Rate in Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Earning Priority Review Designation

June 3, 2021

Gilead Sciences Announces Second Quarter 2021 Dividend

April 28, 2021

Gilead Sciences Announces Steps to Expand Availability of Remdesivir in India

April 25, 2021

Gilead Sciences to Release First Quarter 2021 Financial Results on Thursday, April 29, 2021

April 14, 2021

U.S. FDA Grants Accelerated Approval to Trodelvy® for the Treatment of Metastatic Urothelial Cancer

April 12, 2021

FDA Approves Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival

April 6, 2021

Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Tecartus® in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

March 31, 2021

Gilead Sciences Appoints Flavius Martin, MD as Executive Vice President, Research

March 25, 2021

Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV

March 14, 2021

Gilead’s Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy Through Week 26 in Data Presented at CROI

March 8, 2021

Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults in Four-Year Data Presented at CROI

March 5, 2021

U.S. FDA Approves Yescarta® for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy

March 4, 2021

Gilead Sciences Completes Acquisition of MYR GmbH

March 3, 2021

Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphoma

February 9, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 26 calls. Every call is listed under its year.

Decks

The 5 newest of 51 decks. Every deck is listed under its year.